logo
  

Flutter Entertainment FY19 Profit Down, Sees Flat US EBITDA In FY20; Stock Dips

Shares of Flutter Entertainment plc (FLTR.L) were losing around 5 percent in the early morning trading in London after the sports betting and gaming operator reported Thursday that its fiscal 2019 profit before tax declined 38 percent to 136 million pounds from last year's 219 million pounds.

Earnings per share fell 24 percent to 183.2 pence from 241.7 pence last year. Underlying earnings per share were 303.3 pence, compared to 379.3 pence a year ago.

Underlying EBITDA, pre IFRS 16, was 385 million pounds, down 15 percent from 451 million pounds last year.

Underlying Group EBITDA excluding US (pre IFRS 16) was 426 million pounds, down 9 percent from last year.

Revenue for the year grew 14 percent to 2.14 billion pounds from 1.87 billion pounds last year.

Further, the company proposed a full-year dividend per share of 200 pence, same as last year.

Looking ahead, the company said 2020 has begun strongly, with good customer and revenue momentum across all of its divisions.

The company currently expects the US EBITDA outcome for 2020 to be similar to 2019.

In London, Flutter shares were trading at 8,370.22 pence, down 5.16 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning. Science and technology firm Danaher Corp. (DHR) announced Thursday that it has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance... Biopharmaceutical company Kite Pharma, a part of Gilead Sciences, Inc. (GILD), and biotechnology company Shoreline Biosciences, Inc. announced Thursday a strategic partnership to develop novel cell therapies across a variety of cancer targets. The partnership follows Kite's investment in Shoreline's...
RELATED NEWS
Follow RTT